PGR and breast cancer: This data indicates that the AR-negative cohort had a better chance of attaining pCR and provides evidence that, regardless of the breast cancer subtype and ER/PR/HER2 expression, AR-expressing tumors appear to retain the characteristics of the luminal A subtype when responding to chemotherapeutic agents.